Teva Becomes Strategic Commercialization Partner for Formycon’s Biosimilar Candidate FYB203 (Eylea® / aflibercept) in Major Parts of Europe and Israel

Written by Kirsten Ruehl on 13th January 2025. Posted in Client News.